LPL and hypertriglyceridemia: Volanesorsen is being developed for reduction of triglyceride levels in patients with familial chylomicronemia syndrome (FCS), a rare autosomal recessive disorder characterized by severe hypertriglyceridemia and recurrent pancreatitis due to a deficiency in LPL or associated proteins [7].